Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Padeliporfin→

Padeliporfin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
759457-82-4
Molecular formula
C37H43N5O9PdS
Molecular weight
840.3 g/mol
Drug class
Vascular-targeted photosensitiserphotodynamic antineoplastic agent
Mechanism of action
After local activation with near-infrared laser light, the photosensitiser generates reactive oxygen species within tumour-associated vasculature. This causes local vascular injury, reduced perfusion and tumour necrosis.
Indications / reported uses
  • Vascular-targeted photodynamic therapy studied for focal treatment of localised prostate cancer; product availability and authorised use are jurisdiction-specific.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/padeliporfin · https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Padeliporfin Environmental Risk Assessment (ERA) (the Padeliporfin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.